A Renal Safety Checkpoint for Early High Intensity Statin Therapy in Critically Ill Patients With Acute Coronary Syndrome: A Multidatabase Target Trial Emulation
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
High intensity statins are foundational after acute coronary syndrome (ACS), yet intensive care unit prescribing occurs while renal reserve, perfusion, and interacting therapies are changing. We tested a renal safety checkpoint integrating kidney status, hemodynamic instability, and drug interaction burden to identify when statin intensity may become nonexchangeable.
Methods
We emulated an active-comparator target trial across MIMIC-IV, eICU, and MIMIC-III. Critically ill adults with ACS, acute myocardial infarction, or percutaneous coronary intervention who received high- or moderate-intensity statins within 24 hours were included. The primary outcome was 7-day KDIGO stage 2 or 3 acute kidney injury or incident renal replacement therapy. Eligibility, time zero, treatment assignment, and follow-up were aligned. Database-specific propensity scores, overlap weighting, and standardization addressed confounding and treatment overlap. Safety domains, longitudinal analyses, bootstrap resampling, source omission, and endpoint sensitivities assessed robustness.
Results
Among 5,178 patients, 761 developed the primary outcome, including 223 who initiated renal replacement therapy. Standardized risks were 17.40% with high-intensity therapy and 15.01% with moderate-intensity therapy (risk difference, 2.39 percentage points [95% confidence interval (CI), -0.23 to 5.05]; risk ratio, 1.16 [95% CI, 0.99 to 1.39]). Risk separation was greatest with high hemodynamic instability (5.78 percentage points [95% CI, 1.56 to 9.74]) and high drug-interaction burden (6.24 percentage points [95% CI, -0.44 to 12.19]). Renal replacement therapy showed a 1.33-point risk difference (95% CI, 0.18 to 2.67).
Conclusions
This study moves statin safety assessment beyond fixed dose label or isolated creatinine measurement. The findings support a clinically actionable monitoring strategy in which early statin intensity is reassessed against evolving perfusion, kidney status, and interaction burden. This approach preserves intensive lipid lowering for physiologically suitable patients while identifying a high risk window in which temporary moderation.
Clinical Perspective
What Is New?
-
In critically ill patients with acute coronary syndrome, the average renal contrast between early high- and moderate-intensity statins was modest, while clinically important separation concentrated during hemodynamic instability and high drug-interaction burden.
-
An active-comparator target trial framework linked statin intensity to 6-hour changes in perfusion, kidney function, and concomitant therapy, positioning renal tolerability as a context-sensitive treatment decision.
What Are the Clinical Implications?
-
High-intensity statin therapy remains the cardiovascular anchor, while a focused renal safety checkpoint can identify a transient window for closer surveillance and early intensity reassessment, followed by prompt intensification as physiology stabilizes.
